202 related articles for article (PubMed ID: 37967556)
21. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
[TBL] [Abstract][Full Text] [Related]
22. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
23. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
24. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
25. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
[TBL] [Abstract][Full Text] [Related]
26. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
[TBL] [Abstract][Full Text] [Related]
28. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
29. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
30. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
31. Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.
Liu J; Xu J; Zhang T; Xu K; Bao P; Zhang Z; Xue K; He R; Ma L; Wang Y
Front Immunol; 2022; 13():791158. PubMed ID: 35812372
[TBL] [Abstract][Full Text] [Related]
32. Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma.
Liu L; Jin H; Dong M; Tian J; Li H; Liu Q; Chen Y; Zou Z
Apoptosis; 2022 Dec; 27(11-12):946-960. PubMed ID: 36028785
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
34. Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance.
Zhou M; Kim WY
Clin Cancer Res; 2023 Apr; 29(7):1170-1172. PubMed ID: 36700785
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
37. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
[No Abstract] [Full Text] [Related]
38. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
39. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
40. Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Dong P; Zhang X; Peng Y; Zhang Y; Liu R; Li Y; Pan Q; Wei W; Guo S; Zhang Z; Han H; Zhou F; Liu Y; He L
Clin Cancer Res; 2022 Nov; 28(21):4807-4819. PubMed ID: 36074152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
